Elekta Stock Slides 14% After Mixed Q4 2026 Results

Elekta AB reported mixed financial results for its fiscal fourth quarter ended April 30, 2026, leading to a sharp decline in its share price. The Stockholm-based medical technology company disclosed the figures in an earnings call on May 28, 2026. The company’s stock closed down 14% following the release. Revenue for the quarter increased year-over-year, but profitability metrics failed to meet market expectations.

Context — [why this matters now]

This earnings report arrives during a period of heightened scrutiny for capital equipment providers in the healthcare sector. The last time Elekta saw a single-day drop exceeding 10% was on November 17, 2025, when it fell 11% after warning of component shortages. The current market backdrop features elevated capital costs, with the European Central Bank’s main refinancing rate at 3.50% as of late May 2026.

Investor patience for margin compression has eroded. The catalyst for the sell-off was the revelation that top-line growth did not translate into expected bottom-line gains. Elekta’s management cited persistent but moderating inflationary pressures on raw materials and logistics. However, pricing power for new system installations proved weaker than projected.

The company is navigating a transition phase with its next-generation radiotherapy platforms. Order book strength remains a positive signal, but the market reaction indicates concern over the timeline for improved operational efficiency.

Data — [what the numbers show]

Elekta’s reported Q4 revenue reached SEK 4.85 billion, a 6.2% increase from SEK 4.57 billion in the year-ago quarter. The company’s gross margin contracted to 41.5%, down 180 basis points from 43.3% in Q4 2025. Operating profit fell to SEK 620 million, representing an operating margin of 12.8%, a significant decline from the 15.1% margin reported for the same period last year.

Metric	Q4 2026	Q4 2025	Change
Revenue	SEK 4.85B	SEK 4.57B	+6.2%
Operating Margin	12.8%	15.1%	-230 bps

The stock’s 14% decline erased approximately SEK 8.2 billion in market capitalization. Peers in the medical technology sector showed muted movement, with the iShares Global Medical Devices ETF trading flat on the day. Elekta’s order intake for the quarter was a bright spot, growing 8% year-over-year to SEK 5.1 billion.

Analysis — [what it means for markets / sectors / tickers]

The immediate second-order effect is a reassessment of pure-play radiotherapy equipment makers. Shares of Varian Medical Systems, a primary competitor, dipped 2% in sympathy, reflecting broader sector concerns over margin sustainability. Providers of substitute oncology therapies, such as precision medicine firms, could see incremental benefit as investors rotate.

The key counter-argument to the bearish reaction is the strong order book, which suggests underlying demand for Elekta’s technology remains intact. The sell-off may have been exacerbated by crowded positioning, as the stock was a consensus overweight among European healthcare funds prior to the report.

Flow data indicates institutional sellers dominated the session, with retail buyers attempting to catch the falling knife. The weakness creates a potential opportunity for long-term investors focused on the multi-year upgrade cycle in radiation oncology, but near-term sentiment is decisively negative.

Outlook — [what to watch next]

The next major catalyst is Elekta’s Capital Markets Day scheduled for September 12, 2026, where updated long-term financial targets will be critical for restoring confidence. Investors should monitor the Q1 2027 earnings release in late August for signs of margin stabilization.

Key technical levels for the stock include the SEK 85.00 area, which served as strong support throughout early 2026. A breach below this level could signal a deeper correction. On the upside, reclaiming the SEK 95.00 mark is necessary to signal a reversal of the post-earnings breakdown.

The broader medical equipment sector’s performance will be tested by the Johnson & Johnson MedTech division earnings on July 19, 2026. Strong results there could provide a supportive backdrop for Elekta if it demonstrates improving execution.

Frequently Asked Questions

What does Elekta’s earnings miss mean for long-term investors?

Long-term investors must assess if the margin pressure is a temporary cost issue or a structural problem with pricing. The 8% growth in new orders indicates core demand remains healthy. The focus shifts to management's ability to convert this backlog into profitable sales over the next four quarters, making execution the paramount risk.

How does Elekta’s performance compare to its main competitor, Varian?

Varian, now a division of Siemens Healthineers, has generally reported more stable margins due to its integration into a larger portfolio and service ecosystem. Elekta’s sharper margin decline highlights its exposure as a standalone capital equipment vendor. Both companies face similar macroeconomic headwinds, but Elekta’s concentrated business model amplifies the impact on its stock.

Are supply chain issues still affecting medical device manufacturers in 2026?

Supply chain disruptions have moderated from their 2023-2024 peaks but have not fully resolved. Lead times for specialized semiconductors and certain mechanical components remain extended, though improving. Elekta’s commentary suggests these issues are now a manageable cost pressure rather than a volume constraint, which is a relative improvement from prior years.

Bottom Line

Elekta's order growth failed to offset investor alarm over declining profitability, triggering a severe repricing of the stock.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.